Improve your scientific works. 

Proteios is on a mission to empower preclinical researchers by providing access to biologicals in order to better understand the molecular basis of disease and discover new advanced therapeutics.

Our Story

We are a team of scientists and bioengineers based in Seattle, WA.

We value humility, empathy, vulnerability, and resilience - in life and at work.

Proteios was founded in 2015 to share our novel protein purification technology that was developed at the University of Washington with the research community. The technology is now being expanded to provide for the label-free isolation of any biological, including immune cells and antibodies. 

We believe cell therapies are the future of medicine and that we have a responsibility to make those therapies available to everyone.

We believe the intelligence and diversity of our collective immune systems will unlock discoveries that will change the way disease is treated. 

Our role is to open the doors for researchers to develop new cellular cures using nature’s most innately discerning disease fighters. 

NEWS

  • Proteios receives a $1.7M grant from the Andy Hill CARE Fund to commercialize our next-generation cell isolation and cell therapy manufacturing platform. When commercialized, Proteios will support the isolation of over 20 cell subtypes.

  • Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Innovation Corps (I-Corps) program to assess the market requirements of the Cell Therapy Manufacturing market. A $55K grant is provided to fund the market research.

  • The National Cancer Institute (NCI) contracts with Proteios Technology, Inc. to design/development a bench-scale prototype for Autologous Cell Therapy Manufacturing. The $400K SBIR Phase I contract is in response to Topic 429 – Advanced Manufacturing to Speed Availability of Emerging Autologous Cell-Based Therapies – within the NIH/CDC SBIR Solicitation PHS2021-1. Proteios will incorporate its proven multivariate cell separation technology into the prototype to provide a high-performance, cost-effective instrument for Cell Therapy Manufacturing. Upon successful completion of the Phase I contract, Proteios will be eligible for a $2M SBIR Phase II contract to build an at-scale cGMP instrument for Cell Therapy Manufacturing.

  • The National Science Foundation (NSF) awards a $50K Technical and Business Assistance (TABA) supplemental grant to Proteios Technology, Inc. for commercialization activities associated with their SBIR Phase II project “Removing the Purification Bottleneck in Biopharmaceutical Production.”

  • The National Science Foundation (NSF) awards an SBIR Phase II grant of $750K to Proteios Technology, Inc. for support of the project “Removing the Purification Bottleneck in Biopharmaceutical Production.”

  • Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Innovation Corps (I-Corps) program to assess the market requirements of the Cell Therapy market. A $55K grant is provided to fund the market research.

  • Proteios Technology, Inc. is selected to participate in the National Institutes of Health (NIH) Niche Assessment Program(NAP) to help “jump start” commercialization efforts in the Cell Therapy market.

  • Drs. Alessio Ligabue and Shanqiao Wei join Proteios Technology, Inc. to extend the Proteios Chimera Platform for cell separation and cell therapy manufacturing.

  • The National Institutes of Health (NIH) awards an SBIR Phase I grant of $224K to Proteios Technology, Inc. for support of the project “Simple and Effective Method for Cell Enrichment and Cell Depletion During Cell Therapy.”

  • Proteios, LLC converts to a Washington C-Corp Proteios Technology, Inc.

  • The National Science Foundation (NSF) awards an SBIR Phase I grant of $225K to Proteios, LLC for support of the project “Removing the Purification Bottleneck in Biopharmaceutical Production.”

  • Proteios, LLC moves Into CoMotion Life Science incubator laboratory located on the campus of the University of Washington.

  • Proteios, LLC is founded by Dr. Bob Snyder and Prof. François Baneyx to commercialize the Car9 affinity tag developed in the laboratory of Prof. Baneyx at the University of Washington. Initial development efforts will be focused on recombinant protein/biopharmaceutical purification.

  • The research team of Prof. François Baneyx, professor and chair, Department of Chemical Engineering, University of Washington receives $50K CoMotion Innovation Fund Grant. Car9 affinity chromatography is redefining protein purification with low-cost, environmentally-friendly kits to enable Life Science researchers to quickly and easily purify recombinant proteins produced by genetic engineering. By providing $40K for scientific development and an additional $10K for business development milestones, the CoMotion Innovation Fund will enable Car9 technology to get across the gap between the products of academic research grants and the development needed to attract seed stage investment.

Proteios is driven by the goal to lower the cost of healthcare and to provide advanced therapeutics to a larger patient population.

Research Partners

  • University of Washington

  • UW CoMotion Incubator

  • LARTA Institute

  • Fred Hutch Cancer Center

  • Seattle Children's Research Hospital

  • National Institutes of Health (NIH)

  • National Cancer Institute (NCI)

  • National Science Foundation (NSF)

Out with the slow. In with the new. 

FPLC Protein Purification Kits

Spin Column Protein Purification Kits